Key facts
- This page summarizes Rene Russo's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jun 2021, 16:57.
Rene Russo - 02 Jun 2021 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)
- Reporting relationship
- Director
- Issuer ticker
- XFOR
- Reported as of
- 02 Jun 2021
- Net transaction value
- +$57,000
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2021, 16:57:51 UTC
- Next SEC filing
- 09 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- Derek M. Meisner, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Rene Russo filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 02 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$57,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XFOR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $57,000
- Shares
- +6,000
- Change %
- Price
- $9.50*
- Shares after
- 6,000
- Date
- 02 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,000
- Exercise price
- $9.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date.